An allocator-led investment firm

Building institutional access to women's health.

Calabar backs exceptional managers and founders building in women's health through specialist fund commitments, direct co-investments and selected secondaries.

Explore our approach Meet the leadership

Calabar Capital is an investment platform currently in development.

02 — Investment Leadership

Investment experience supported by institutional governance.

Maryann Selfe, FCCA

Founder, Managing Partner and Chief Investment Officer

Maryann leads Calabar's investment strategy, manager underwriting and portfolio construction. She spent almost 20 years at Credit Suisse as an institutional allocator, where she co-built the framework for investment manager selection and due diligence and held investment-risk responsibility across multi-asset portfolios totalling approximately $100 billion. She has reviewed more than 1,000 investment managers and sponsored more than 90 allocations across public and private markets into funds and direct investments.

Maryann Selfe on LinkedIn

Jillian MacNab

Co-Founder, Head of Governance and Operations

Jillian leads Calabar's governance and operational development. A Swiss financial-services lawyer, she brings more than twenty-five years of experience across regulation, investment structures and institutional governance.

Jillian MacNab on LinkedIn

Investment Committee

Institutional allocation informed by specialist investment expertise.

Calabar's Investment Committee combines institutional portfolio construction with specialist expertise in women's-health venture investing, commercialisation and cross-border healthcare investing.

Maryann Selfe, Chair of the Investment Committee at Calabar Capital

Maryann Selfe, FCCA

Chair, Investment Committee

Maryann chairs the Investment Committee and leads Calabar's manager underwriting, portfolio construction and investment decisions across fund commitments, co-investments and secondaries. She assesses commitment sizing, portfolio fit, diversification and look-through risk.

Dominnique Karetsos

Investment Committee Member

Women's-Health Venture Investing and Commercialisation

Dominnique Karetsos is co-creator of Amboy Street Ventures, one of the earliest venture funds dedicated to women's and sexual health. She brings direct experience in fund building, investment-committee decision-making, and assessing and scaling women's-health companies.

Sara Zhou

Investment Committee Member

Cross-Border Healthcare Investing

Sara Zhou is a cross-border healthcare investor and adviser with deep networks across the United States, Europe and Asia. A former Investment Director at Shanghai Creation Investment, she helped establish four overseas funds totalling $50 million and led due diligence on more than 20 global healthcare investments.

Advisers

Guided by specialist and institutional perspective.

Calabar's advisers extend the firm's expertise beyond investment selection, providing independent perspectives on institutional wealth, clinical relevance and healthcare adoption.

Dr Mara Catherine Harvey

Dr Mara Catherine Harvey brings more than 25 years of international wealth-management leadership, including experience as a private-banking CEO and Supervisory Board member. Her expertise in family wealth, intergenerational transfer, impact finance and financial inclusion brings an important private-wealth and institutional-allocation perspective to Calabar Capital.

Dr Abraham (Nick) Morse

Dr Abraham (Nick) Morse is a Harvard-trained physician and women's-health specialist with more than 25 years of experience across clinical practice, digital health and healthcare innovation. He advises Calabar Capital on clinical developments, healthcare delivery and the translation of scientific advances into scalable businesses.

03 — The Investment Thesis

Longstanding gaps in women's health are becoming investable opportunities.

Historical underinvestment has left longstanding gaps in women's health.

Today, advances in sex-specific science and technology, together with demographic shifts, are translating these gaps into investable opportunities.

A growing market

PwC estimates the broader global women's-health market at approximately $430–$440 billion today, with the potential to exceed $600 billion by 2030.

Specialist innovation

Specialist companies are developing new diagnostics, therapeutics, medical devices and models of care across women's health.

Fragmented access

The opportunity spans multiple clinical disciplines, sectors, stages and geographies. No single fund or direct investment provides representative access, while healthcare's idiosyncratic risks make specialist expertise and diversification essential.

Source: PwC, 2026. Market estimate includes core women's health and major adjacent conditions.

04 — The Investment Approach

Multiple routes to a fragmented opportunity.

Calabar accesses women's-health innovation through specialist fund commitments, direct co-investments and selected secondaries.

Each route plays a distinct role, allowing Calabar's investment vehicles to build exposure across different clinical disciplines, sectors, stages and geographies.

Specialist fund commitments

Investments in specialist managers with the expertise, networks and access to identify and support exceptional companies across women's health.

Direct co-investments

Selective investments alongside trusted managers in high-conviction companies where Calabar sees the potential for attractive risk-adjusted returns.

Selected secondaries

Opportunistic access to more mature companies and fund interests where greater visibility, attractive pricing or earlier liquidity may improve the investment profile.

Allocator-led portfolio construction

Calabar evaluates every investment in the context of the whole portfolio — combining rigorous underwriting, look-through exposure analysis and disciplined portfolio construction to manage concentration and idiosyncratic healthcare risk.

Calabar's platform and any future investment activities remain under development and subject to the completion of all applicable legal, regulatory and operational arrangements.

05 — Selected Research

Research that sharpens investment judgement.

Investing in women's health requires more than recognising unmet need. It requires an understanding of how the market is developing, where specialist expertise sits and how different opportunities contribute to an investment portfolio.

Calabar's research examines market structure, capital flows, specialist manager ecosystems and the portfolio implications of investing across women's health. Maryann publishes selected analysis through The Billion Dollar Blindspot.

Research01

How to Invest in Women's Health

An institutional framework for the principal routes available to investors—and the different risks, capabilities and portfolio implications of each.

Read the Article

Research02

Is Women's Health a Good Investment Opportunity for Private Wealth?

An assessment of the opportunity through the lens of demand, capital flows, portfolio construction and private-wealth allocation.

Read the Article

Research03

Why Women's Health Requires a Portfolio Approach

An examination of why the opportunity spans multiple clinical disciplines, business models, stages and geographies and why no single fund or direct investment captures its full breadth.

Coming soon

Explore The Billion Dollar Blindspot

06 — Contact

Start a conversation.

We welcome enquiries from specialist investment managers and others working across the women's-health investment ecosystem.

For investment managers

Do you manage a specialist investment strategy focused on women's health?

If you would like to introduce your firm and strategy to Calabar, book a manager briefing call.

Book a Manager Briefing

General enquiries

For institutional, strategic, media or other enquiries, please contact: hello@calabarcapital.com